Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.

Journal of ovarian research - 2 May 2022

Marchocki Zibi, Tone Alicia, Virtanen Carl, de Borja Richard, Clarke Blaise, Brown Theodore, May Taymaa

Abstract excerpt

BACKGROUND: Patients treated with neoadjuvant chemotherapy (NACT) for advanced high-grade serous ovarian carcinoma (HGSC) have a higher rate and shorter time to platinum-resistant recurrence compared to patients treated with primary cytoreductive surgery (PCS) and adjuvant chemotherapy. The purpose of this study is to determine the impact of NACT on somatic mutation status in platinum-sensitive and resistant...

Topics

Join the communities discussing this publication.

Cystadenocarcinoma, Serous
Endometrial and Cervical Cancer Treatments
Mutation
Neoadjuvant Therapy
Neoplasms, Glandular and Epithelial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Ovarian cancer diagnosis and treatment

Ovarian Neoplasms

PARP inhibition in cancer therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 35501919
DOI: 10.1186/s13048-022-00983-5
PMCID: PMC9059396

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.PMID 35501919Read ↗

Impact of Neoadjuvant Chemotherapy on Somatic Mutation Status in High-grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer.Semantic proximity Read ↗

Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.Semantic proximity Read ↗

The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 studySemantic proximity Read ↗

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.Semantic proximity Read ↗

Comprehensive Genomic Characterization in Ovarian Low-Grade and Chemosensitive and Chemoresistant High-Grade Serous Carcinomas.Semantic proximity Read ↗

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) ApproachSemantic proximity Read ↗

TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.Semantic proximity Read ↗

The Role of Secondary Cytoreductive Surgery in Primary Platinum-sensitive Recurrent HGSOC Patients With Different BRCA1/2 Mutation Status: a Retrospective StudySemantic proximity Read ↗

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian CancerSemantic proximity Read ↗

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.